Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-SIRIUS I: Switching from originator infliximab (Remicade) to infliximab biosimilar in RA remission
jRCTs071190030Completed
- Sponsor
- Celltrion Healthcare
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in rheumatoid arthritis (RA), sponsored by Celltrion Healthcare. Primary endpoint: Clinical relapse rate. Started Jul 2020; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071190030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190030.